U.S. health regulator the at the FDA turned down an application to approve Novartis‘ experimental heart failure drug due to insufficient evidence that it improves symptoms, Novartis said. Novartis said in […]
U.S. health regulator the at the FDA turned down an application to approve Novartis‘ experimental heart failure drug due to insufficient evidence that it improves symptoms, Novartis said. Novartis said in […]